We have generated a novel, humanized anti-NKG2A therapeutic mAb that is being developed for treatment of solid tumors such as ovarian cancer and hematological malignancies. In this study, we investigated the potential clinical role of this new therapeutic mAb in vitro and in humanized mouse models.
Methods

Therapeutic anti-NKG2A mAb
The murine anti-human NKG2A mAb clone Z270 was generated and characterized as previously described (18) . Details of the generation and characterization of humanized Z270 will be reported elsewhere. In brief, the murine Z270 mAb was humanized by grafting the Kabat CDRs onto a human acceptor framework, and expressed in CHO cells. Recombinant humanized clones were screened to identify those that retained binding to CD94/NKG2A with similar affinity as the original murine mAb. Clones were then counter-screened on CD94-NKG2C and -E, to ensure specificity for CD94-NKG2A. The selected humanized clone, designated humZ270, or IPH2201, was expressed as an IgG4 with a single point mutation in the Fc heavy chain to prevent formation of half-antibodies.
Cell isolation
All neoplastic cells were obtained from patients' bone marrow aspirates or peripheral blood. All the lympho-hematopoietic normal cell types were obtained from healthy donors. Patients and donors provided prior written informed consent in accordance with the Declaration of Helsinki. Mice that succumbed to leukemia or EBV lympho-proliferative disease were assessed for AML or EBV organ infiltration by flow cytometry analysis with a specific panel of anti-human mAb which previously characterized the neoplastic cells (see below).
In a model of engrafted disease, we infused the same mouse strain with AML or EBV cell lines. When bone marrow engraftment was around 20-30%, mice were given escalating doses of IL-2 activated NKG2A+NK cells (1x10 6 ) that had been pre-treated with anti-human NKG2A mAb (10μg/1x10 6 cells/ml) (from 1 to 10 million per mouse, intravenously).
Mice that died of leukemia or lymphoma were assessed for AML or EBV organ infiltration by flow cytometry analysis using a specific panel of anti-human mAb (see below).
In other mouse models, the day after irradiation female ten week old NSG mice were given intravenously 10x10 6 From day 40 onwards mice were evaluated for EBV or AML engraftment with a combination of anti-human CD45 mAb and mAb specific for AML or EBV cell line (anti-CD45, anti-CD20, anti-CD19, anti-IgM, antikappa, anti-lambda, anti-CD23, anti-CD3, anti-CD33, anti-CD34, anti-CD56, anti-CD117, anti-CD8, CD4, CD34 mAbs, eBioscience).
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Mice that succumbed to EBV lympho-proliferative disease or leukemia were assessed for EBV or AML organ infiltration by flow cytometry analysis with a combination of anti-human mAbs (see above). Mice that survived were sacrificed after 100 days, and tumor organ infiltration analyzed with the same antibody combination.
Statistical analyses
Student's t test was used to compare variables and was applied by Graphpad Prism 5. Kaplan-Meier method evaluated murine survival.
All P values are two-sided and were considered significant at P < .05.
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Results
In vitro treatment with anti-human NKG2A antibody triggers NKG2A + NK cell lysis of HLA-E + hematopoietic lineage targets.
In order to assess the susceptibility of normal and neoplastic haematopoietic lineage targets to alloreactive NK cell lysis, we generated 
